Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Immunome and keeping the price target at $20.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles Zhu has given his Buy rating due to a combination of factors that highlight Immunome’s promising developments and strategic positioning. The company is on track with its pivotal varegacestat data expected by the end of 2025, which is a significant milestone for their RINGSIDE Phase 3 trial in desmoid tumors. This confidence is bolstered by observed responses across multiple dose levels in their ROR1-targeted ADC program, indicating potential efficacy.
Furthermore, Immunome’s pipeline is robust, with plans to initiate a Phase 1 trial for their FAP-targeted RLT and file INDs for preclinical ADCs throughout 2026. Management’s optimism about the dataset’s performance on key metrics, such as overall response rate and tumor volume reduction, further supports the Buy rating. Despite a high short interest, the company’s strategic flexibility in unblinding data and managing cash burn enhances its investment appeal.
According to TipRanks, Zhu is a 5-star analyst with an average return of 15.9% and a 61.70% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Zymeworks, IDEAYA Biosciences, and Kura Oncology.
In another report released on November 3, Piper Sandler also maintained a Buy rating on the stock with a $21.00 price target.